News

An Interview with Martino Laurenzi, M.D., MPH

Clinical Research Scientist for the TB Alliance

This video was recorded on November 13, 2009 at Johns Hopkins University.

Dr. Martino Laurenzi
Dr. Martino Laurenzi

Dr. Laurenzi, an expert in clinical development and community health, is a Clinical Research Scientist at the TB Alliance, where his responsibilities include the oversight of clinical trials. Dr. Laurenzi has long been involved in public health research; the Gubbio Study, which he started in 1982 in the Italian town for which it is named, is one of the longest standing population-based epidemiological studies for the screening of cardiovascular risk factors.

Prior to joining the TB Alliance, Dr. Laurenzi spent twenty-five years at Merck & Co., most recently as Executive Medical Director, Specialty Products. While at Merck, he managed protocol development and implementation for a wide range of projects in several therapeutic areas, and provided medical input and guidance to clinical research programs from Phase II through Phase V trials. He was also extensively involved in Clinical Research Operations, and managed Merck Research Laboratories’ Medical Departments in the Middle European Region and in Middle East Africa. From 1990-1993 Dr. Laurenzi was Director, Medical Affairs and Epidemiology, at Merck’s facility in Rome, Italy. Since 1987, Dr. Laurenzi has served as an Adjunct Assistant Professor in the Department of Community Health and Preventive Medicine at Northwestern University.

Born in the U.S., Dr. Laurenzi grew up in Italy, where he received his Doctorate of Medicine and Surgery from the University of Rome. He obtained his Masters of Public Health from Columbia University in 1981. His research and his interests have led him to many different countries. He has lived in the U.S. since 1993.

More News
30 Mar 2021
Médecins Sans Frontières (MSF) published a press release on World TB Day 2021 announcing their clinical trial, TB-Practecal , investigating novel treatment for MDR-TB has stopped enrolling earlier than originally planned due to promising results. The trial's independent data safety and monitoring...
3 Feb 2021
Last week, the World Health Organization (WHO) held a consultation to discuss the definition of extensively drug resistant (XDR) tuberculosis. The meeting was held to discuss novel treatment regimens and diagnostics for drug-resistant TB and determine its impact on the definition of XDR-TB. The...
10 Dec 2020
The Stop TB Partnership Working Group on New TB Vaccines (WGNV), Working Group on New TB Drugs (WGND), and New Diagnostics Working Group (NDWG) are developing an online course specifically designed for advocates and affected communities to provide a base of knowledge in TB research and to generate...